Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 30.02% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.1 billion (up 26.77% YoY), and the FY2025 full-year result was $1.3 billion, up 26.33% from the prior year.
• Liabilities and Shareholders Equity improved to $1.4 billion in Q1 2026, from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $531.8 million in Q1 2023.
• A 5-year average of $892.4 million and a median of $853.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity decreased 13.78% in 2023 and surged 60.44% in 2024, its largest moves.
• Tracing KRYS's Liabilities and Shareholders Equity over 5 years: stood at $558.4 million in 2022, then jumped by 46.54% to $818.4 million in 2023, then increased by 29.02% to $1.1 billion in 2024, then advanced by 26.33% to $1.3 billion in 2025, then increased by 4.74% to $1.4 billion in 2026.
• Business Quant data shows KRYS's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.